Compare PMM & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMM | LCTX |
|---|---|---|
| Founded | 1989 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.4M | 301.7M |
| IPO Year | N/A | 1996 |
| Metric | PMM | LCTX |
|---|---|---|
| Price | $6.35 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 86.8K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $109.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.65 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $5.77 | $0.85 |
| 52 Week High | $6.52 | $2.09 |
| Indicator | PMM | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 41.61 |
| Support Level | $6.06 | N/A |
| Resistance Level | $6.40 | $1.80 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 100.00 | 16.75 |
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.